Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce the appointment of Frédéric Duchesne, former President and Chief Executive Officer of the Pharmaceuticals Division of Pierre Fabre Laboratories, to the Board of the Company as a Non-Executive Director with immediate effect.
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has finalised the development plan for its key MTD201 Q-Octreotide product, a treatment for acromegaly and neuroendocrine tumours (NET) based on the Company’s unique polymer microsphere technology, Q-Sphera™ for sustained drug delivery.
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, today announces its audited financial results for the twelve-month period ended 31 December 2018.
Midatech Pharma plc (AIM: MTPH), the R&D company focused on delivering innovative oncology and rare disease products to patients, announces its results for the six months ended 30 June 2018
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and immunotherapy, today announces a trading update for the six months ended 30 June 2018.
Midatech Pharma (AIM: MTPH), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announces its audited financial results for the twelve-month period ended 31 December 2017.